Literature DB >> 15191981

Nalbuphine and slow release morphine.

Jason Smith1, Henry Guly.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191981      PMCID: PMC421789          DOI: 10.1136/bmj.328.7453.1426

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  7 in total

1.  Excessive morphine requirements after pre-hospital nalbuphine analgesia.

Authors:  N Robinson; N Burrows
Journal:  J Accid Emerg Med       Date:  1999-09

2.  The effect of pre-hospital administration of intravenous nalbuphine on on-scene times.

Authors:  G S Johnson; H R Guly
Journal:  J Accid Emerg Med       Date:  1995-03

3.  Antagonist effects of nalbuphine in opioid-dependent human volunteers.

Authors:  K L Preston; G E Bigelow; I A Liebson
Journal:  J Pharmacol Exp Ther       Date:  1989-03       Impact factor: 4.030

4.  The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.

Authors:  M W Lo; F H Lee; W L Schary; C C Whitney
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Prehospital intravenous nalbuphine administered by paramedics.

Authors:  J A Chambers; H R Guly
Journal:  Resuscitation       Date:  1994-03       Impact factor: 5.262

6.  Nalbuphine analgesia in the prehospital setting.

Authors:  J K Stene; L Stofberg; G MacDonald; R A Myers; A Ramzy; B Burns
Journal:  Am J Emerg Med       Date:  1988-11       Impact factor: 2.469

7.  Excessive morphine requirements after pre-hospital nalbuphine analgesia.

Authors:  K P Houlihan; R G Mitchell; A D Flapan; D J Steedman
Journal:  J Accid Emerg Med       Date:  1999-01
  7 in total
  2 in total

1.  Sedate with caution.

Authors:  J M Lutz; W F de Mello
Journal:  Emerg Med J       Date:  2007-01       Impact factor: 2.740

Review 2.  Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review.

Authors:  Aleksandra Kotlinska-Lemieszek; Pål Klepstad; Dagny Faksvåg Haugen
Journal:  Drug Des Devel Ther       Date:  2015-09-16       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.